Results 261 to 270 of about 591,861 (351)

Automated real-time collection of pathogen-specific diagnostic data: Syndromic infectious disease epidemiology [PDF]

, 2018
et al,, Storch, Gregory A
core   +1 more source

Chemical Profiling, In Silico and In Vitro Studies to Identify Potential CDK2 and mTOR Inhibitor From Selaginella inaequalifolia (Hook. & Grev.) Spring Ethanolic Extracts

Chemistry &Biodiversity, EarlyView.
ABSTRACT The current study is aimed to reveal the phytoprofile of Selaginella inaequalifolia (Hook. & Grev.) Spring using GC–MS and predict the drug properties, toxicity, biological properties of S. inaequalifolia ethanolic extracts (SiEE) using in silico methods and in vitro toxicity assays, namely, MTT and BSLB assay.
Johnson Marimuthu Alias Antonysamy, Sivaraman Arumugam, Robin Charles Antony Arulraj, Anne Wincy Jacob Thomas, Henrique D. M. Coutinho   +4 more
wiley   +1 more source

ResMicroDb: a comprehensive database and analysis platform for the human respiratory microbiome. [PDF]

Nucleic Acids Res
Ji X, Qian Q, Zhang H, Cai Q, Zhang K, Xiao J, Jiang X, Li M.   +7 more
europepmc   +1 more source

Endovascular Stenting for Pulmonary Vein Stenosis Following Atrial Fibrillation Ablation: From Diagnosis to Intervention

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Pulmonary vein stenosis (PVS) is an uncommon but serious complication of atrial fibrillation (AF) ablation, often misinterpreted as primary pulmonary disease. Timely identification is essential to prevent irreversible injury and to guide appropriate referral for interventional management. Case Presentations Through the discussion of
Cristina Aurigemma, Marco Busco, Francesco Bianchini, Gabriella Locorotondo, Francesca Graziani, Annalisa Pasquini, Enrico Romagnoli, Mattia Lunardi, Lazzaro Paraggio, Francesco Varone, Andrea Smargiassi, Bruno Iovene, Riccardo Marano, Carlo Trani, Francesco Burzotta   +14 more
wiley   +1 more source

Mitochondria and the Actin Cytoskeleton in Neurodegeneration

Cytoskeleton, EarlyView.
ABSTRACT Mitochondrial dysfunction and cytoskeletal disorganization are widely recognized hallmarks of neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).
Shivani Tuli, Preet Patel, Aneri Shethji, David Gau   +3 more
wiley   +1 more source

450 nm diode laser in the treatment of upper respiratory tract diseases

А. А. Кривопалов, P. A. Shamkina, M. Yu. Korkmazov, Anton Glushchenko, V. M. ZHURBA, V.Yu. Chuchin   +5 more
openalex   +1 more source

Non‐Syndromic Tumefactive Demyelinating Lesions in the Pediatric Population: Four Case Reports and Review of the Literature

Annals of the Child Neurology Society, EarlyView.
ABSTRACT Introduction Tumefactive demyelinating lesions (TDLs) are large lesions (> 2 cm) seen in demyelinating syndromes such as multiple sclerosis, myelin oligodendrocyte glycoprotein antibody‐associated disorder, and neuromyelitis optica spectrum disorder. They rarely occur in children and most often have a monophasic course.
Elizabeth C. Ballinger, Hannah F. Todd, Jonathan M. Yarimi, Timothy E. Lotze, Nikita M. Shukla, Kristen S. Fisher, Alexander J. Sandweiss   +6 more
wiley   +1 more source

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh, Chaim M. Brickman, Peter Lloyd, Ashish Kalra, Subhabrata Biswas, Arkadeep Sinha, Alex Mulvanny, Sumathi Sivapalasingam, Oren M. Becker, Aaron Deykin   +9 more
wiley   +1 more source

Population Pharmacokinetics of Clesrovimab in Preterm and Full‐Term Infants

Clinical Pharmacology &Therapeutics, EarlyView.
Clesrovimab is a half‐life extended monoclonal antibody targeting the respiratory syncytial virus fusion protein. Three studies (phase Ib/IIa [MK‐1654‐002], phase IIb/III [CLEVER], and phase III [SMART]) were conducted to evaluate the efficacy, safety, and pharmacokinetics (PK) of clesrovimab in infants.
Ziheng Hu, Farina Hellmann, Xiaowei Zang, Nele Plock, Keyur Parmar, Radha A. Railkar, S. Y. Amy Cheung, Brian M. Maas, Ferdous Gheyas   +8 more
wiley   +1 more source